Clinical Trials Browser

INDUSTRY × Myelodysplastic Syndromes × Gemtuzumab × Clear all

NCT04849910 2025-07-29

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Phase 1/2 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute